MDT-AP-3325
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 7.6
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.764558949
- umap2_2d
- 0.818131128
- umap1_3d
- 1.001004341
- umap2_3d
- -3.775081758
- umap3_3d
- -1.021980826
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.390
- G2M_CHECKPOINT+0.290
- WNT_BETA_CATENIN_SIGNALING+0.240
- TGF_BETA_SIGNALING+0.180
- UV_RESPONSE_DN+0.180
- PROTEIN_SECRETION+0.160
- E2F_TARGETS+0.130
- HEME_METABOLISM+0.100
- MYC_TARGETS_V1+0.050
- PEROXISOME+0.030
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.490
- INFLAMMATORY_RESPONSE-0.470
- COMPLEMENT-0.430
- INTERFERON_GAMMA_RESPONSE-0.430
- COAGULATION-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900006 | — | — | 0.925 |
| 2 | MDT-AP-3265 | Med | Medulloblastoma | 0.908 |
| 3 | MDT-AP-3311 | Med | Medulloblastoma | 0.903 |
| 4 | SJEPD031175_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.899 |
| 5 | s_150324_3b | EPN | Posterior Fossa EPN | 0.896 |
| 6 | TCGA-A7-A3IZ-01A-11R-A213-07 | — | B | 0.887 |
| 7 | SJEPD030770_D1.RNA-Seq | EPN | EPN Tumor | 0.871 |
| 8 | SRR662871 | GTEX | — | 0.865 |
| 9 | TCGA-CR-7370-01A-11R-2132-07 | — | — | 0.863 |
| 10 | MDT-AP-3246 | Med | Medulloblastoma | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.050 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |